

IN THE CLAIMS

1. (original) A controlled release system, comprising 3~10wt% of temozolomide and biodegradable polymeric materials.
2. (original) The controlled release system according to claim 1, which is implantable tablet.
3. (currently amended) The controlled release system according to claim 1 [[or 2]], wherein the said biodegradable polymeric materials are selected from the group consisting of polyethylene, polypropylene, polyethylene terephthalate, plasticized polyvinyl chloride, cross-linked polyester, polycarbonate, polysulfone, polystyrene, poly(2-pentene), polymethyl methacrylate, poly (1,4-phenylene), polytetrafluoroethylene, and poly(anhydride).
4. (original) The controlled release system according to claim 3, wherein the said biodegradable polymeric materials are poly(anhydride).
5. (original) The controlled release system according to claim 4, wherein the said poly(anhydride) is one condensed from 3,4-bis(p-carboxyphenoxy) propane (CPP) and sebacic acid (SA).
6. (original) The controlled release system according to claim 5, wherein said 3,4-bis(p-carboxyphenoxy) propane (CPP) and sebacic acid (SA) are at the ratio of 20 to 80.
7. (original) A process of preparing the temozolomide controlled release tablets, comprising:
 - a. Dissolving the polymeric materials in a solvent to give a solution of polymeric materials;

ATTORNEY DOCKET NO. 16188.0001U1
U.S. Application No. 10/529,454
International Application No. PCT/CN2003/000383

- b. Dispersing temolozomide in or mixing temolozomide with said solution of polymeric materials to produce a mixture of polymeric materials and temolozomide;
 - c. Spray-drying said mixture of polymeric materials and temolozomide to obtain microspheres; and
 - d. Tableting said microspheres to obtain implantable tablets.
8. (original) The process according to claim 7, wherein the said polymeric materials are ones condensed from 3,4-bis(p-carboxyphenoxy) propane (CPP) and sebacic acid (SA).
9. (currently amended) The process according to claim 7 [[or 8]], wherein said 3,4-bis(p-carboxyphenoxy) propane (CPP) and sebacic acid (SA) are at the ratio of 20 to 80.
10. (original) The process according to claim 7, wherein the said solvent in step (a) is methylene chloride.
11. (original) A process of preparing the temozolomide controlled release tablets, comprising:
- a. Dissolving the polymeric materials in a solvent to give a solution of polymeric materials;
 - b. Adding temolozomide into said solution of polymeric materials and ultrasonic-emulsifying the resultant solution to obtain a first emulsion;
 - c. Mixing said first emulsion with polyvinyl alcohol (PVA), followed by evaporating the solvent to obtain hard microspheres;
 - d. Eliminating PVA and residual solvent by washing with water to obtain microspheres; and
 - e. Tableting said microspheres to obtain implantable tablets.
12. (original) The process according to claim 11, wherein the said polymeric materials are ones condensed from 3,4-bis(p-carboxyphenoxy) propane (CPP) and sebacic acid (SA).

ATTORNEY DOCKET NO. 16188.0001U1
U.S. Application No. 10/529,454
International Application No. PCT/CN2003/000383

13. (currently amended) The process according to claim 11 [[or 12]], wherein said 3,4-bis(p-carboxyphenoxy) propane (CPP) and sebacic acid (SA) are at the ratio of 20 to 80.

14. (original) The process according to claim 11, wherein the said solvent in step (a) is methylene chloride.